Dutch health innovation consultancy that helps EU research consortia translate cancer, AI, and genomics projects into market-ready products.
PNO Life Sciences & Health is the health-sector arm of PNO Group, a Dutch innovation consultancy specializing in research valorization — helping EU-funded projects translate scientific results into market-ready products and clinical applications. They provide project management, exploitation strategy, and business development support within large health research consortia. Their coordinated project UTILE was explicitly an "EU Health Innovation Marketplace" for valorizing FP7 and H2020 health research, which reveals their core business model. Across 16 projects they consistently occupy support and advisory roles rather than performing lab research themselves.
Coordinated UTILE (EU Health Innovation Marketplace) and joined 15 other projects in support/advisory roles, with 5 as third-party contributor — a pattern typical of innovation consultancies.
Supported cancer-focused projects across immunotherapy (IMMUNISA), liquid biopsies (ELBA), nanomedicine (PRECIOUS), immune imaging (Immune-Image), AI-driven oncology (OPTIMA), and prostate cancer big data (PIONEER).
Recent participation in BIGPICTURE (digital pathology), OPTIMA (AI for cancer treatment), and INTERVENE (genomic prediction) signals growing focus on AI-driven health technologies.
Involved in INTERVENE (biobank-based genomics), ConcePTION (pregnancy pharmacovigilance biobank), and PIONEER (big data for prostate cancer).
Third-party or partner roles in MSCA training networks InCeM, PREDICT, ELBA, ENTWINE, and TICARDIO, likely providing career development and industry liaison services.
In 2015–2018, PNO-LSH focused on cancer biology and therapeutic translation — projects like IMMUNISA (HPV immunotherapy), ELBA (liquid biopsies), and PRECIOUS (cancer nanomedicine) dominated their portfolio. From 2019 onward, the focus shifted markedly toward AI, digital tools, and data-driven medicine: BIGPICTURE (digital pathology AI), OPTIMA (AI-guided cancer treatment), and INTERVENE (polygenic risk scores from biobank data). This evolution mirrors the broader health sector's digital transformation, but also suggests PNO-LSH is deliberately positioning itself to support the commercialization of AI-health products.
PNO-LSH is moving toward AI and data-intensive health projects, making them a relevant valorization partner for any consortium working on clinical AI, digital pathology, or genomic prediction tools.
PNO-LSH almost never leads — they coordinated just 1 of 16 projects. Their dominant pattern is joining large consortia (298 unique partners across 30 countries) as a participant or third-party contributor, providing innovation management and exploitation support rather than core research. This makes them a low-friction partner to bring on board: they integrate into existing consortium structures, handle non-scientific work packages, and connect research outputs to industry and market needs.
With 298 unique consortium partners across 30 countries, PNO-LSH has one of the broadest networks you'll find in a health-sector SME. Their reach spans nearly all of Europe, with no narrow geographic bias — a direct result of their consultancy model that plugs into diverse consortia.
PNO-LSH occupies a specific niche: they are not a research lab, a hospital, or a tech company — they are the people who help health research projects reach the market. Their value is in exploitation planning, industry engagement, and turning scientific deliverables into business cases. For consortium builders, adding PNO-LSH solves the common problem of "we have great science but no commercialization strategy" — and their 298-partner network means they can also open doors to potential end-users and licensees.
